Dr. Reddy’s infuses Rs. 565 crore in its Russian subsidiary
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Subscribe To Our Newsletter & Stay Updated